Featured Publications
Early Outcomes With the Evolut PRO Repositionable Self-Expanding Transcatheter Aortic Valve With Pericardial Wrap
Forrest JK, Mangi AA, Popma JJ, Khabbaz K, Reardon MJ, Kleiman NS, Yakubov SJ, Watson D, Kodali S, George I, Tadros P, Zorn GL, Brown J, Kipperman R, Saul S, Qiao H, Oh JK, Williams MR. Early Outcomes With the Evolut PRO Repositionable Self-Expanding Transcatheter Aortic Valve With Pericardial Wrap. JACC Cardiovascular Interventions 2018, 11: 160-168. PMID: 29348010, DOI: 10.1016/j.jcin.2017.10.014.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic ValveAortic Valve StenosisCause of DeathEchocardiographyFemaleHeart Valve ProsthesisHemodynamicsHumansMaleMitral Valve InsufficiencyPericardiumProspective StudiesProsthesis DesignRisk FactorsSeverity of Illness IndexStrokeTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeUnited StatesConceptsSelf-expanding transcatheter aortic valveSevere symptomatic aortic stenosisEvolut PRO valveSymptomatic aortic stenosisTranscatheter aortic valveAortic stenosisParavalvular leakAortic valveValve Academic Research Consortium-2 criteriaIndependent echocardiographic core laboratoryTranscatheter aortic valve replacementTranscatheter aortic valve systemEchocardiographic core laboratoryPrimary safety endpointPrimary efficacy endpointRemainder of patientsAortic valve replacementProportion of patientsProsthetic valve regurgitationSupra-annular valveEffective orifice areaDisabling strokeCause mortalityEfficacy endpointSafety endpoint3-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis
Forrest J, Deeb G, Yakubov S, Gada H, Mumtaz M, Ramlawi B, Bajwa T, Teirstein P, DeFrain M, Muppala M, Rutkin B, Chawla A, Jenson B, Chetcuti S, Stoler R, Poulin M, Khabbaz K, Levack M, Goel K, Tchétché D, Lam K, Tonino P, Ito S, Oh J, Huang J, Popma J, Kleiman N, Reardon M, Investigators L, Sorajja P, Byrne T, Kirshner M, Bajwa T, Crouch J, Coselli J, Silva G, Hebeler R, Stoler R, Islam A, Rousou A, Poulin M, Khabbaz K, Bladergroen M, Fail P, Netherland D, Lam K, Tonino W, Sudre A, Berthoumieu P, Tchétché D, Khalili H, Hughes G, Harrison J, De A, Tsau P, van Mieghem N, Larbalestier R, Yong G, Agarwal S, Martin W, Park S, Kleiman N, Reardon M, Mohammadi S, Rodes-Cabau J, Sparling J, Elkins C, Ganzel B, Matthews R, Starnes V, Ando K, Chevalier B, Farge A, DeFrain M, Muppala M, Combs W, Bagur R, Chu M, Fontana G, Dev V, Leya F, Tuchek J, Inglessis I, Jassar A, Piazza N, Lacappelle K, Steinberg D, Katz M, Wang J, Kozina J, Slachman F, Merritt R, Chawla A, Jensen B, Alvarez J, Gooley R, Smith J, Ibrahim R, Cartier R, Rovin J, Fujita T, Rutkin B, Yakubov S, Song H, Zahr F, Miyagawa S, Rajagopal V, Kauten J, Gada H, Mumtaz M, Bhindi R, Brady P, Batra S, Davis T, Iskander A, Heimansohn D, Hermiller J, Takamisawa I, Haldis T, Yamazaki S, Teirstein P, Tada N, Saito S, Merhi W, Leung S, Muller D, Heijmen R, Petrossian G, Robinson N, Knight P, Ling F, Radhakrishnan S, Fremes S, Lehr E, Gafoor S, Noel T, Walton A, Resar J, Adams D, Sharma S, Lilly S, Tadros P, Zorn G, Dauerman H, Ittleman F, Horlick E, Feindel C, Welt F, Sharma V, Markowitz A, Carroll J, Fullerton D, Griffith B, Gupta A, de Marchena E, Salerno T, Chetcuti S, Deeb G, Sultan I, Goel K, Pasupati S, Kon N, Zhao D, Ramlawi B, Forrest J. 3-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis. Journal Of The American College Of Cardiology 2023, 81: 1663-1674. PMID: 36882136, DOI: 10.1016/j.jacc.2023.02.017.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementAortic valve replacementLow-risk patientsCause mortalityPrimary endpointParavalvular regurgitationValve replacementEvolut Low Risk trialLow surgical risk patientsSurgical aortic valve replacementGreater paravalvular regurgitationLow-risk trialsData comparing outcomesLow-risk studiesSupra-annular valveEchocardiographic outcomesSecondary endpointsSurgery groupTAVR patientsRisk patientsSurgery patientsAortic stenosisPacemaker placementTreatment armsMean age
2024
3-Year Outcomes From the Evolut Low Risk TAVR Bicuspid Study
Zahr F, Ramlawi B, Reardon M, Deeb G, Yakubov S, Song H, Kleiman N, Chetcuti S, Gada H, Mumtaz M, Leung S, Merhi W, Rovin J, DeFrain M, Muppala M, Kauten J, Rajagopal V, Huang J, Ito S, Forrest J. 3-Year Outcomes From the Evolut Low Risk TAVR Bicuspid Study. JACC Cardiovascular Interventions 2024, 17: 1667-1675. PMID: 39048253, DOI: 10.1016/j.jcin.2024.05.017.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic ValveAortic Valve StenosisBicuspid Aortic Valve DiseaseBioprosthesisFemaleHeart Valve DiseasesHeart Valve ProsthesisHemodynamicsHumansMaleMiddle AgedPostoperative ComplicationsProspective StudiesProsthesis DesignRecovery of FunctionRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeUnited StatesConceptsTranscatheter aortic valve replacementRates of all-cause mortalityAll-cause mortalityAortic stenosisThoracic Surgeons Predicted Risk of Mortality scoreThoracic Surgeons Predicted RiskSevere paravalvular aortic regurgitationBicuspid aortic valve anatomyRisk of Mortality scoreEchocardiographic core laboratoryLow-surgical risk patientsAortic valve anatomyKaplan-Meier ratesLow surgical riskClinical events committeeAortic valve replacementSevere aortic stenosisParavalvular aortic regurgitationPermanent pacemaker implantationBicuspid aortic stenosisFavorable hemodynamic performanceEvaluated 3 yearsAttempted implantEchocardiographic outcomesAortic regurgitation
2022
Propensity-Matched 1-Year Outcomes Following Transcatheter Aortic Valve Replacement in Low-Risk Bicuspid and Tricuspid Patients
Deeb GM, Reardon MJ, Ramlawi B, Yakubov SJ, Chetcuti SJ, Kleiman NS, Mangi AA, Zahr F, Song HK, Gada H, Mumtaz M, Heiser J, Merhi W, Murrah CP, Noel T, Kirshner M, Byrne T, Ito S, Huang J, Forrest JK. Propensity-Matched 1-Year Outcomes Following Transcatheter Aortic Valve Replacement in Low-Risk Bicuspid and Tricuspid Patients. JACC Cardiovascular Interventions 2022, 15: 511-522. PMID: 35272776, DOI: 10.1016/j.jcin.2021.10.027.Peer-Reviewed Original ResearchMeSH KeywordsAortic ValveAortic Valve StenosisHeart Valve ProsthesisHumansProspective StudiesRiskTranscatheter Aortic Valve ReplacementTreatment OutcomeConceptsTranscatheter aortic valve replacementAortic valve replacementValve replacementAortic stenosisTricuspid patientsOutcomes Following Transcatheter Aortic Valve ReplacementEvolut Low Risk trialLow surgical risk patientsIndependent clinical events committeeBicuspid aortic stenosisLow-risk trialsSurgical risk patientsTricuspid aortic stenosisPropensity-matched groupsSerious adverse eventsClinical events committeeIndependent core laboratoryBicuspid aortic valveEffective orifice areaTricuspid groupCause mortalityPrimary endpointTAVR patientsAdverse eventsRisk patients
2021
A randomized evaluation of the TriGuard™ HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial
Lansky AJ, Makkar R, Nazif T, Messé S, Forrest J, Sharma R, Schofer J, Linke A, Brown D, Dhoble A, Horwitz P, Zang M, DeMarco F, Rajagopal V, Dwyer MG, Zivadinov R, Stella P, Rovin J, Parise H, Kodali S, Baumbach A, Moses J. A randomized evaluation of the TriGuard™ HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial. European Heart Journal 2021, 42: 2670-2679. PMID: 34000004, DOI: 10.1093/eurheartj/ehab213.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementEfficacy endpointCerebral embolic protection devicesTranscatheter aortic valve implantationCentral nervous system injuryCerebral embolic lesionsCerebral ischemic lesionsHealth Stroke ScalePrimary efficacy endpointPrimary safety outcomeAortic valve replacementAortic valve implantationEmbolic protection devicesNervous system injuryDiffusion-weighted magnetic resonanceMontreal Cognitive AssessmentEffectiveness endpointCause mortalityCerebral protectionSafety endpointStroke ScaleValve implantationValve replacementI trialIschemic lesionsRandomized Evaluation of TriGuard 3 Cerebral Embolic Protection After Transcatheter Aortic Valve Replacement REFLECT II
Nazif TM, Moses J, Sharma R, Dhoble A, Rovin J, Brown D, Horwitz P, Makkar R, Stoler R, Forrest J, Messé S, Dickerman S, Brennan J, Zivadinov R, Dwyer MG, Lansky AJ, Investigators R. Randomized Evaluation of TriGuard 3 Cerebral Embolic Protection After Transcatheter Aortic Valve Replacement REFLECT II. JACC Cardiovascular Interventions 2021, 14: 515-527. PMID: 33663779, DOI: 10.1016/j.jcin.2020.11.011.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementAortic valve replacementSafety endpointValve replacementProcedure-related ischemic strokeCerebral embolic protectionComposite efficacy endpointPrimary safety endpointCerebral embolizationCerebral protectionEfficacy endpointII trialCerebral injuryIschemic strokeEmbolic protectionPatientsDrug AdministrationUS sitesU.S. FoodEndpointData reviewTrialsMulticenterEmbolizationInjury
2017
1-Year Results in Patients Undergoing Transcatheter Aortic Valve Replacement With Failed Surgical Bioprostheses
Deeb GM, Chetcuti SJ, Reardon MJ, Patel HJ, Grossman PM, Schreiber T, Forrest JK, Bajwa TK, O’Hair D, Petrossian G, Robinson N, Katz S, Hartman A, Dauerman HL, Schmoker J, Khabbaz K, Watson DR, Yakubov SJ, Oh JK, Li S, Kleiman NS, Adams DH, Popma JJ. 1-Year Results in Patients Undergoing Transcatheter Aortic Valve Replacement With Failed Surgical Bioprostheses. JACC Cardiovascular Interventions 2017, 10: 1034-1044. PMID: 28521921, DOI: 10.1016/j.jcin.2017.03.018.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic ValveAortic Valve InsufficiencyAortic Valve StenosisEchocardiographyFemaleHeart Valve ProsthesisHeart Valve Prosthesis ImplantationHemodynamicsHumansKaplan-Meier EstimateMaleMiddle AgedProspective StudiesProsthesis FailureQuality of LifeRecovery of FunctionRecurrenceReoperationRisk FactorsTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeConceptsSelf-expanding transcatheter aortic valve replacementTranscatheter aortic valve replacementAortic valve replacementMajor stroke rateAortic regurgitationValve replacementStroke rateValve hemodynamicsSevere native aortic valve stenosisSuccessful transcatheter aortic valve replacementNative aortic valve stenosisNew permanent pacemaker implantationSevere residual aortic regurgitationValve prosthesis-patient mismatchMean aortic gradientMean valve gradientResidual aortic regurgitationSevere aortic regurgitationProsthesis-patient mismatchCause mortality ratesIndependent core laboratoryModerate aortic regurgitationPermanent pacemaker implantationAortic valve stenosisAortic valve hemodynamics
2016
Neurologic Complications of Unprotected Transcatheter Aortic Valve Implantation (from the Neuro-TAVI Trial)
Lansky AJ, Brown D, Pena C, Pietras CG, Parise H, Ng VG, Meller S, Abrams KJ, Cleman M, Margolis P, Petrossian G, Brickman AM, Voros S, Moses J, Forrest JK. Neurologic Complications of Unprotected Transcatheter Aortic Valve Implantation (from the Neuro-TAVI Trial). The American Journal Of Cardiology 2016, 118: 1519-1526. PMID: 27645761, DOI: 10.1016/j.amjcard.2016.08.013.Peer-Reviewed Original ResearchMeSH KeywordsAged, 80 and overAortic ValveAortic Valve StenosisBrainBrain IschemiaDiffusion Magnetic Resonance ImagingFemaleFollow-Up StudiesHumansIncidenceIntracranial EmbolismMalePostoperative ComplicationsPrognosisProspective StudiesRisk AssessmentRisk FactorsSurvival RateTranscatheter Aortic Valve ReplacementUnited StatesConceptsTranscatheter aortic valve implantationAortic valve implantationNeurologic injuryValve implantationNeurologic impairmentMagnetic resonance imaging lesionsCognitive AssessmentMontreal Cognitive Assessment scoreCerebral ischemic lesionsNew neurologic impairmentSubclinical cerebral infarctsDiffusion-weighted magnetic resonance imagingTotal lesion volumeCognitive Assessment scoreMontreal Cognitive AssessmentMagnetic resonance imagingCerebral embolizationCerebral infarctsNeurologic complicationsCerebral infarctionImaging lesionsMost patientsOvert strokeConsecutive patientsIschemic lesions
2015
Safety and performance of a novel embolic deflection device in patients undergoing transcatheter aortic valve replacement: results from the DEFLECT I study.
Baumbach A, Mullen M, Brickman AM, Aggarwal SK, Pietras CG, Forrest JK, Hildick-Smith D, Meller SM, Gambone L, den Heijer P, Margolis P, Voros S, Lansky AJ. Safety and performance of a novel embolic deflection device in patients undergoing transcatheter aortic valve replacement: results from the DEFLECT I study. EuroIntervention 2015, 11: 75-84. PMID: 25868876, DOI: 10.4244/eijy15m04_01.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAlloysAortic ValveAortic Valve StenosisBrain IschemiaBrazilCardiac CatheterizationCognitionCognition DisordersDiffusion Magnetic Resonance ImagingEmbolic Protection DevicesEuropeFemaleHeart Valve ProsthesisHeart Valve Prosthesis ImplantationHumansIntracranial EmbolismMalePredictive Value of TestsProspective StudiesProsthesis DesignRisk FactorsSeverity of Illness IndexStrokeTime FactorsTreatment OutcomeUltrasonography, Doppler, TranscranialConceptsTranscatheter aortic valve replacementAortic valve replacementValve replacementNew cerebral ischemic lesionsCerebral diffusion-weighted magnetic resonance imagingCerebral ischemic lesionsDays post procedurePrimary safety endpointDiffusion-weighted magnetic resonance imagingMajor cerebral arteriesTotal lesion volumeMagnetic resonance imagingSafety endpointIschemic lesionsTAVR proceduresCerebral arteryCerebral circulationConsecutive subjectsPost procedureAortic archHistorical controlsLesion volumeResonance imagingDW-MRIPatients
2013
Evaluation of XIENCE V Everolimus-Eluting and Taxus Express2 Paclitaxel-Eluting Coronary Stents in Patients With Jailed Side Branches From the SPIRIT IV Trial at 2 Years
Forrest JK, Lansky AJ, Meller SM, Hou L, Sood P, Applegate RJ, Wang JC, Skelding KA, Shah A, Kereiakes DJ, Sudhir K, Cristea E, Yaqub M, Stone GW. Evaluation of XIENCE V Everolimus-Eluting and Taxus Express2 Paclitaxel-Eluting Coronary Stents in Patients With Jailed Side Branches From the SPIRIT IV Trial at 2 Years. The American Journal Of Cardiology 2013, 111: 1580-1586. PMID: 23499270, DOI: 10.1016/j.amjcard.2013.01.330.Peer-Reviewed Original ResearchConceptsSPIRIT IV trialMajor adverse cardiac eventsAdverse cardiac eventsClinical outcomesXIENCE VTarget lesionsCardiac eventsNovo native coronary artery lesionsIschemia-driven target vessel revascularizationTwo-year clinical outcomesNative coronary artery lesionsSPIRIT IIISide branchesXIENCE V EverolimusTarget lesion failureTarget vessel revascularizationCoronary artery lesionsPercutaneous coronary interventionSuperior clinical outcomesTreatment of patientsCoronary stent systemDrug-eluting stentsDiverse patient populationsEverolimus-ElutingSPIRIT IV